Baseline characteristics
| Type 1 diabetes | Type 2 diabetes | |
|---|---|---|
| N=8 | N=12 | |
| Age (years) | 63 [24–74] | 56 [39–65] |
| Female sex (%) | 3 (38) | 3 (25) |
| BMI (kg/m2) | 23.2 [21.6–24.5] | 28.3 [26.4–30.7] |
| Fat percentage (%) | 27.1 [23.6–33.0] | 28.9 [25–35.1] |
| Insulin therapy (n): CSII/MDI/BD | 4/4/0 | 3/8/1 |
| Oral blood glucose-lowering agents (%) | ||
| Metformin | – | 10 |
| SU | – | 1 |
| Other | – | 0 |
| HbA1c (mmol/mol) | 59 [46–70] | 55 [42–82] |
| Presence of microvascular complications | ||
| Nephropathy (n) | 0 | 1 |
| Neuropathy (n) | 2 | 4 |
| Retinopathy (n) | 2 | 1 |
| Diabetes duration (years) | 14 [7–24] | 13 [4–25] |
Data are presented as n (%), mean (SD) or median [range].
BD, twice daily mix insulin; BMI, body mass index; CSII, continuous subcutaneous insulin infusion; HbA1c, glycated hemoglobin; MDI, multiple daily injections; SU, sulfonylurea derivate.